A novel cancer therapeutic using thrombospondin 1 in dendritic cells

Tzu Yang Weng, Shih Shien Huang, Meng Chi Yen, Chi Chen Lin, Yi Ling Chen, Chiu Mei Lin, Wei Ching Chen, Chih Yang Wang, Jang Yang Chang, Ming Derg Lai

研究成果: 雜誌貢獻文章同行評審

21 引文 斯高帕斯(Scopus)


Induction of thrombospondin 1 (TSP-1) is generally assumed to suppress tumor growth through inhibiting angiogenesis; however, it is less clear how TSP-1 in dendritic cells (DCs) influences tumor progression. We investigated tumor growth and immune mechanism by downregulation of TSP-1 in dendritic cells. Administration of TSP-1 small hairpin RNA (shRNA) through the skin produced anticancer therapeutic effects. Tumor-infiltrating CD4 + and CD8 + T cells were increased after the administration of TSP-1 shRNA. The expression of interleukin-12 and interferon-γ in the lymph nodes was enhanced by injection of TSP-1 shRNA. Lymphocytes from the mice injected with TSP-1 shRNA selectively killed the tumor cells, and the cytotoxicity of lymphocytes was abolished by depletion of CD8 + T cells. Injection of CD11c + TSP-1-knockout (TSP-1-KO) bone marrow-derived DCs (BMDCs) delayed tumor growth in tumor-bearing mice. Similarly, antitumor activity induced by TSP-1-KO BMDCs was abrogated by depletion of CD8 + T cells. In contrast, the administration of shRNAs targeting TSP-2, another TSP family member, did not extend the survival of tumor-bearing mice. Finally, TSP-1 shRNA functioned as an immunotherapeutic adjuvant to augment the therapeutic efficacy of Neu DNA vaccination. Collectively, the downregulation of TSP-1 in DCs produces an effective antitumor response that is opposite to the protumor effects by silencing of TSP-1 within tumor cells.
頁(從 - 到)292-302
期刊Molecular Therapy
出版狀態已發佈 - 1月 1 2014

ASJC Scopus subject areas

  • 分子醫學
  • 分子生物學
  • 遺傳學
  • 藥理
  • 藥物發現


深入研究「A novel cancer therapeutic using thrombospondin 1 in dendritic cells」主題。共同形成了獨特的指紋。